RxDoctor Payments Data

Brandon Fisher, DO

Radiation Oncology · Ogden, UTNPI 1275789026

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 23 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $122 and has fallen 71.2% since, to $35 in 2025. That places this record below the midpoint for radiation oncology clinicians in UT, where the typical reported total is $531.

$397in general payments, 2019–2025

Across 23 payments — averaging $17.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$56
  • Johnson & Johnson$36
  • Boston Scientific$33
  • Siemens Medical Solutions USA, Inc.$31
  • Bayer$28
  • AbbVie$24
  • plus $189 from 11 others

What the payments were for

  • Food & beverage$397100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$397 in reported general payments places this provider in the 40th percentile of 49 radiation oncology providers in Utah.

See all radiation oncology providers in Utah

Medicare billing

Part B allowed, 2024
$89,885
Medicare patients
116
Services billed
991

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tamsulosin Hcl19$66

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Ogden

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →